Ultragenyx gains on $210 million US FDA voucher sale
07/10/2026 15:06
BUZZ-Ultragenyx gains on $210 million US FDA voucher sale ** Shares of drugmaker Ultragenyx Pharmaceutical RARE.O rise 2.8% to $14.87
** Ultragenyx agrees to sell an FDA Priority Review Voucher for $210 million in cash
** Co received the voucher upon the FDA approval of Genglycos, its treatment for glycogen storage disease type Ia, also known as Von Gierke disease
** Under a licensing agreement, Ultragenyx pays 20% of the voucher sale proceeds to the U.S. National Institutes of Health after the deal closes
** Ultragenyx did not immediately respond to a Reuters request for information on the buyer
** Genglycos has a US per-patient list price of $2.7 million
** As of last close, stock down ~35% YTD
(Reporting by Kamal Choudhury in Bengaluru)
Recent news on Ultragenyx Pharmaceutical
See all newsBrief: Ultragenyx Pharmaceutical Enters Settlement Agreement With Navinta On Dojolvi Patent Litigation - SEC Filing
Ultragenyx gains on $210 million US FDA voucher sale
Brief: Ultragenyx Pharmaceutical - Under Deal With U.S. Department Of Health Co To Pay 20% Of Prv Sale Proceeds To Nih
Brief: Ultragenyx Enters Into Agreement To Sell Rare Pediatric Disease Priority Review Voucher For $210 Million
U.S. STOCKS ON THE MOVE-CoreWeave, StubHub, Ultragenyx